Resolutions at the annual general meetings in Medivir on 10 May 2012

Stockholm – Medivir AB (OMX: MVIR), a research-based specialty pharmaceutical
company focused on infectious diseases, today held their AGM.

Election of the board of directors and auditor
The annual general meeting in Medivir Aktiebolag (publ) on 10 May 2012 resolved,
in accordance with the nomination committee's proposal, that the number of board
members shall be six with no deputy board members. Björn C. Andersson, Anna Malm
Bernsten, Ingemar Kihlström and Göran Pettersson were re-elected as board
members and Rolf A. Classon och Anders Hallberg were newly elected as board
members. Göran Pettersson was re-elected chairman of the board.
PricewaterhouseCoopers was re-elected as auditor.

Remuneration to the board of directors
The annual general meeting also resolved on remuneration to the board of
directors in accordance with the nomination committee's proposal. The
remuneration to the board shall amount to not more than SEK 2,055,000 allocated
as follows. The chairman shall receive SEK 470,000 and the other members
entitled to remuneration shall receive SEK 210,000 each. Remuneration for work
performed in relation to committees shall be paid in a total amount of SEK
535,000, whereof SEK 210,000 shall be allocated to the audit committee (whereof
SEK 80,000 to the convener of the committee and SEK 65,000 to each of the other
two members), SEK 115,000 to the remuneration committee (whereof SEK 65,000 to
the convener of the committee and SEK 50,000 to the other member) and SEK
210,000 to the R&D committee (whereof SEK 80,000 to the convener of the
committee and SEK 65,000 to each of the other two members). For board members
resident outside of Europe (this currently applies to board member Rolf A.
Classon), in addition to the ordinary remuneration, compensation of SEK 20,000
shall be paid per physical board meeting. However, such additional compensation
shall never exceed SEK 100,000 per year.

Remuneration guidelines for senior executives
The annual general meeting approved the proposal of the board of directors on
remuneration guidelines for senior executives. Under the guidelines, the company
shall offer a total remuneration on market norms and enable skilled senior
executives to be hired and retained. The remuneration to senior executives may
consist of basic salary, variable salary, incentive programmes resolved by the
general meeting, pension and other benefits.

Authorisation to issue new shares
The annual general meeting resolved, in accordance with the nomination
committee's proposal, to authorise the board, for the period up to the next
annual general meeting, to adopt decisions, whether on one or several occasions
and whether with or without pre-emption rights for the shareholders, to issue
new shares of class B to an amount not exceeding in total 10 per cent of the
total number of outstanding class B-shares in the company following utilization
of the authorisation. New issue may be made with or without provisions
concerning non-cash consideration, set-off or other provision specified in
Chapter 13 Section 5, first paragraph, 6, of the Swedish Companies Act. The
purpose of the authorisation is to provide the board with flexibility in its
work to secure that the company, in a suitable way, can be provided with capital
for the financing of the business, acquisitions of companies and products, and
to enable a broadening of the ownership of the company.

Nomination committee
The annual general meeting resolved to appoint a nomination committee for the
annual general meeting 2013 substantially in accordance with the same procedure
as the preceding year. In brief, this entails that the chairman of the board
shall contact the three largest shareholders in respect of voting power by the
end of the third quarter. These three shareholders shall be offered to appoint
one representative each for the nomination committee. In addition, the chairman
of the board shall be included as a member of the nomination committee.

Approval of profit and loss accounts and balance sheets, and discharge from
liability of the board members and the managing director
The profit and loss account and balance sheet as well as the consolidated profit
and loss account and consolidated balance sheet were approved, and the managing
director and the board members were discharged from liability with respect to
their respective management of the company for financial year 2011.

Appropriation of the company’s profit or loss
The annual general meeting resolved, in accordance with the nomination
committee's proposal, that the company’s results shall be carried forward.

For additional information, please contact
Rein Piir, EVP Corporate Affairs & IR, Medivir
Office line +46 8 440 6550 or Mobile +46 708 537292

About Medivir
Medivir is an emerging research-based specialty pharmaceutical company focused
on the development of high-value treatments for infectious diseases. Medivir has
world class expertise in polymerase and protease drug targets and drug
development which has resulted in a strong infectious disease R&D portfolio. The
Company’s key pipeline asset is TMC435, a novel protease inhibitor in phase III
clinical development for hepatitis C that is being developed in collaboration
with Janssen Pharmaceuticals.

In June 2011, Medivir acquired the specialty pharmaceutical company BioPhausia
to ensure timely commercialisation of TMC435 in the Nordic markets, once
approved.

Medivir’s first product, the unique cold sore product Xerese®/Xerclear®, was
launched on the US market in 2011. Xerese®/Xerclear®, which has been approved in
both the US and Europe, is being launched in collaboration with GlaxoSmithKline
to be sold OTC in Europe, Japan and Russia. Rights in North America, Canada and
Mexico were sold to Meda AB in June 2011. Medivir has retained the Rx rights for
Xerclear® in Sweden and Finland.

For more information on Medivir, please see the company’s website:
www.medivir.com